Australia's TGA approves suspension for subfoveal CNV from wet AMD

Australia's Therapeutic Goods Administration (TGA) approved Alcon's 15-mg anecortave acetate suspension (Retaane) for the treatment of subfoveal choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD). The drug should be used where there is a classic component.

As part of a clinical trial agreement, the company will provide the suspension to the U.S. National Eye Institute for a study of wet AMD.

The multicenter, randomized, prospective clinical trial will investigate the long-term safety and efficacy of 15-mg anecortave acetate suspension in patients with all forms of wet AMD and who are undergoing intravitreal bevacizumab (Avastin, Genentech) therapy.